创新的固体脂质纳米粒子配方用于眼疗法和相关专利:系统性审查
Bakr Ahmed1, Nitika Saini1, Veluchamy A Barathi2
1University Instiute of Pharmaceutical Sciences (UIPS), Panjab University, Chandigarh 160014, India.
概括
固体脂质纳米颗粒 (SLN) 通过提高生物可用性和实现持续释放来增强眼部药物输送,克服眼睛障碍,以治疗诸如绿眼和干眼综合征等疾病. 这些纳米粒子为传统治疗提供了更安全,更有效的替代方案.
科学领域:
- 眼科药物输送是眼科药物输送.
- 纳米医学是一种纳米医学.
- 材料科学是一种材料科学.
背景情况:
- 由于解剖学和生理障碍,眼部疾病带来了重大的药物输送挑战.
- 传统的眼部治疗方法,如眼滴和注射,具有局限性,包括快速清除,侵入性和全身副作用.
- 固体脂质纳米颗粒 (SLN) 成为眼科应用的有希望的先进药物输送平台.
研究的目的:
- 系统地审查固体脂质纳米颗粒 (SLN) 对于眼部药物输送的疗效.
- 评估SLN在提高生物可用性,实现持续药物释放和克服眼障碍方面的潜力.
- 为了将SLN与传统的输送系统和其他纳米粒子平台进行比较,用于治疗前后段眼部疾病.
主要方法:
- 从2010年到2024年,在主要的科学数据库 (PubMed,Scopus,Web of Science,Google Scholar) 中进行了全面的文献搜索.
- 纳入标准集中在使用SLN用于眼部应用的原始研究和专利上,遵守PRISMA 2020指南.
- 数据提取包括活性药物成分,颗粒特征 (大小,泽塔潜力) 和治疗结果,以及偏差评估风险.
主要成果:
- 28项研究和20项专利符合标准,调查了含有各种活性药物成分 (API) 的SLN,如阿托瓦斯塔丁和大麻素.
- SLN 显示显著增强眼部生物可用性 (例如,阿托瓦斯塔丁可达 12 倍),持续药物释放 (24-96 小时),以及改善角膜透性 (可达 287%的增加).
- 专利的SLN配方显示出卓越的稳定性和有效性,在评估的研究中没有观察到明显的眼睛毒性.
结论:
- 固体脂质纳米颗粒 (SLN) 为眼部药物输送提供了一种变革性的方法,通过增加透性和控制释放来增强治疗结果.
- SLN在安全性,可扩展性和商业可行性方面具有优势,解决了当前眼睛治疗的局限性.
- 需要进一步的研究来克服工业翻译和监管障碍,重点关注设计质量 (QbD) 原则和先进的表征技术.
相关概念视频
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...